Sarepta Therapeutics, Inc. $SRPT Stock Holdings Boosted by State of Alaska Department of Revenue

State of Alaska Department of Revenue increased its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 343.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 49,113 shares of the biotechnology company’s stock after acquiring an additional 38,043 shares during the period. State of Alaska Department of Revenue owned approximately 0.05% of Sarepta Therapeutics worth $946,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Byrne Asset Management LLC acquired a new stake in shares of Sarepta Therapeutics in the third quarter valued at approximately $33,000. Blue Trust Inc. grew its holdings in Sarepta Therapeutics by 542.3% in the 2nd quarter. Blue Trust Inc. now owns 3,282 shares of the biotechnology company’s stock worth $56,000 after buying an additional 2,771 shares in the last quarter. GAMMA Investing LLC increased its position in Sarepta Therapeutics by 285.6% in the 3rd quarter. GAMMA Investing LLC now owns 3,089 shares of the biotechnology company’s stock valued at $60,000 after acquiring an additional 2,288 shares during the period. PNC Financial Services Group Inc. raised its stake in Sarepta Therapeutics by 61.8% during the 2nd quarter. PNC Financial Services Group Inc. now owns 3,779 shares of the biotechnology company’s stock valued at $65,000 after acquiring an additional 1,444 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Sarepta Therapeutics by 25.4% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,042 shares of the biotechnology company’s stock worth $69,000 after acquiring an additional 819 shares during the period. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Stock Down 0.8%

SRPT stock opened at $21.13 on Monday. The firm has a market cap of $2.21 billion, a PE ratio of -7.02, a P/E/G ratio of 0.46 and a beta of 0.48. Sarepta Therapeutics, Inc. has a 12 month low of $10.41 and a 12 month high of $120.05. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.95 and a quick ratio of 1.79. The firm has a 50 day simple moving average of $20.78 and a 200 day simple moving average of $19.70.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.15). Sarepta Therapeutics had a negative net margin of 11.25% and a negative return on equity of 4.85%. The company had revenue of $399.36 million during the quarter, compared to the consensus estimate of $331.51 million. During the same period in the prior year, the company posted $0.62 EPS. Sarepta Therapeutics’s quarterly revenue was down 14.5% on a year-over-year basis. Equities research analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SRPT has been the topic of a number of research analyst reports. HC Wainwright reissued a “sell” rating on shares of Sarepta Therapeutics in a report on Wednesday, January 14th. Wells Fargo & Company decreased their target price on shares of Sarepta Therapeutics from $50.00 to $45.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. Royal Bank Of Canada boosted their price target on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the stock a “sector perform” rating in a research report on Thursday, January 8th. Guggenheim reduced their price target on shares of Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Finally, Barclays lowered their price objective on shares of Sarepta Therapeutics from $22.00 to $20.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 5th. Nine equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and six have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $33.76.

Insider Activity

In other news, COO Ian Michael Estepan sold 13,187 shares of the company’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total transaction of $294,201.97. Following the completion of the sale, the chief operating officer directly owned 193,300 shares of the company’s stock, valued at $4,312,523. This represents a 6.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 7.60% of the stock is owned by company insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.